RxDoctor Payments Data

Peter Belott, MD

Clinical Cardiac Electrophysiology · la Mesa, CANPI 1316913833

Payments from drug & device makers

$131,689in general payments, 2019–2025

Across 274 payments — averaging $480.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$104K
  • Convatec Inc.$17K
  • Acutus Medical, Inc.$5K
  • Biotronik Inc.$3K
  • Abbott$1K
  • Biosense Webster, Inc.$523
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$98,10487%
  • Travel & lodging$4,2804%
  • Food & beverage$9,8159%
  • Education$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,689 in reported general payments places this provider in the 75th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$148,316
Medicare patients
226
Services billed
1,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$128,364
EntrestoSacubitril/Valsartan64$89,895
XareltoRivaroxaban24$23,347
JardianceEmpagliflozin13$14,230
BrilintaTicagrelor16$7,794
Metoprolol Succinate194$2,557
Mexiletine Hcl20$1,977
Verapamil ErVerapamil Hcl62$1,484
Amiodarone Hcl86$1,145
Carvedilol90$914
Digoxin18$621
Furosemide94$592
Potassium Chloride30$528
Atorvastatin Calcium38$434
Losartan Potassium43$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$128,364134 claims
NovartisEntresto$32$89,89564 claims
Johnson & JohnsonXarelto$267$23,34724 claims
Boehringer IngelheimJardiance$49$14,23013 claims
AstraZenecaBrilinta$111$7,79416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →